Literatura científica selecionada sobre o tema "Minimal pharmacophores"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Minimal pharmacophores".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Minimal pharmacophores"
Mortier, Jérémie, Pratik Dhakal e Andrea Volkamer. "Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces". Molecules 23, n.º 8 (6 de agosto de 2018): 1959. http://dx.doi.org/10.3390/molecules23081959.
Texto completo da fontePetrikaite, Vilma, Eduardas Tarasevišius e Alvydas Pavilonis. "New ethacridine derivatives as the potential antifungal and antibacterial preparations". Medicina 43, n.º 8 (11 de agosto de 2007): 657. http://dx.doi.org/10.3390/medicina43080084.
Texto completo da fonteSpasov, Alexander, Irina Ovchinnikova, Olga Fedorova, Yulia Titova, Denis Babkov, Vadim Kosolapov, Alexander Borisov et al. "Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury". Molecules 28, n.º 2 (11 de janeiro de 2023): 741. http://dx.doi.org/10.3390/molecules28020741.
Texto completo da fonteMishra, Pranjali, Muskan Srivastav, Yashveer Gautam, Monal Singh, Neeraj Verma, Deepak S. Kapkoti, Shailendra P. Singh, Anil K. Singh e Devendra P. Rao. "A REVIEW IN CURCUMINOIDS: CHEMISTRY, ANTICANCER ACTIVITY AND FUTURE PROSPECTS". INDIAN DRUGS 61, n.º 05 (28 de maio de 2024): 7–23. http://dx.doi.org/10.53879/id.61.05.14041.
Texto completo da fonteMaatuf, Yossi, Matan Geron e Avi Priel. "The Role of Toxins in the Pursuit for Novel Analgesics". Toxins 11, n.º 2 (23 de fevereiro de 2019): 131. http://dx.doi.org/10.3390/toxins11020131.
Texto completo da fonteWermelinger, Guilherme Freimann, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro e Bruno Kaufmann Robbs. "A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma". Biomedicines 11, n.º 6 (14 de junho de 2023): 1711. http://dx.doi.org/10.3390/biomedicines11061711.
Texto completo da fonteBourne, Yves, Gerlind Sulzenbacher, Laurent Chabaud, Rómulo Aráoz, Zoran Radić, Sandrine Conrod, Palmer Taylor, Catherine Guillou, Jordi Molgó e Pascale Marchot. "The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism". Marine Drugs 22, n.º 4 (27 de março de 2024): 149. http://dx.doi.org/10.3390/md22040149.
Texto completo da fonteCaldas Lopes, Eloisi, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero e Malcolm A. S. Moore. "Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity". Blood 126, n.º 23 (3 de dezembro de 2015): 1556. http://dx.doi.org/10.1182/blood.v126.23.1556.1556.
Texto completo da fonteVawhal, Pallavi Kishor, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan et al. "Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay". Molecules 28, n.º 3 (19 de janeiro de 2023): 1004. http://dx.doi.org/10.3390/molecules28031004.
Texto completo da fonteRobertson, Gregory T., Eric J. Bonventre, Timothy B. Doyle, Qun Du, Leonard Duncan, Timothy W. Morris, Eric D. Roche, Dalai Yan e A. Simon Lynch. "In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci". Antimicrobial Agents and Chemotherapy 52, n.º 7 (julho de 2008): 2324–34. http://dx.doi.org/10.1128/aac.01651-07.
Texto completo da fonteTeses / dissertações sobre o assunto "Minimal pharmacophores"
Su, Li. "Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches". Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Texto completo da fonteThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation
Capítulos de livros sobre o assunto "Minimal pharmacophores"
Rijkers, Dirk T. S., Jack A. J. den Hartog e Rob M. J. Liskamp. "Structure-Activity Studies on the Corticotropin Releasing Factor Antagonist Astressin, Minimal Sequence Necessary for Antagonistic Activity: Implications for a New Pharmacophoric Model". In Peptides: The Wave of the Future, 727–28. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_339.
Texto completo da fonte